ArticleAnnals of medicine2024
Outcomes and predictors of progression in progressive pulmonary fibrosis.
Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cough burden in progressive pulmonary fibrosis: a systematic review with narrative synthesis.Health and quality of life outcomes · 2026Pooled it
- Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Review
- Phase-resolved functional lung magnetic resonance imaging for evaluation of lung perfusion and ventilation in fibrosing interstitial lung diseases.Insights into imaging · 2026Article
- Development and internal validation of a machine learning-based model for predicting 2-year mortality in interstitial lung disease.Respiratory research · 2026Article
- Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature.ERJ open research · 2026Review
- Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study.BMC pulmonary medicine · 2026Article
- Temperature- and humidity-modified associations between ambient air pollution and syncope outpatient visits: a time series analysis in Beijing, China.Scientific reports · 2026Article
- Distinct phenotypic clusters associated with progressive pulmonary fibrosis in anti-synthetase syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF): Real-World outcomes from a Single-Center study.Lung India : official organ of Indian Chest Society · 2026Article
- A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index.Respiratory research · 2025Article
- Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren's syndrome patients: new roles for old friends.Clinical and experimental medicine · 2025Article
- Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis-associated interstitial lung disease.BMC pulmonary medicine · 2025Article
- Lung ultrasound for assessing disease progression in UIP and NSIP: a comparative study with HRCT and PFT/DLCO.BMC pulmonary medicine · 2025Article
- Predicting biomarkers of progressive pulmonary fibrosis: morphological, cytokine profile, and clinical portrait.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgressive pulmonary fibrosis (PPF) is a general term for a class of interstitial lung diseases (ILDs) characterized by a progressive fibrosing (PF) phenotype. Patients with PPF have decreased lung function, exercise ability, and quality of life. The purpose of this study was to investigate the clinical characteristics, potential associated factors for disease progression, and survival outcomes of patients in the PPF population.
methodsThis study retrospectively reviewed the data of patients diagnosed with ILD between January 2011 and December 2022 at The First Affiliated Hospital of Ningbo University. A PF phenotype was defined based on the criteria that were used in the PPF clinical practice guidelines, which led to the identification of 92 patients with a PF phenotype among the 177 patients with fibrotic ILD. Baseline clinical information and laboratory parameters were collected and analysed in our cohort.
resultsPatients in the PPF group had higher tumour marker levels and lower pulmonary function test results at baseline than did those in the non-PPF group. According to the multivariate logistic regression analysis, age >65 years (OR 2.71, 95% CI 1.26-5.89;
conclusionsPatients who were older, had high CA-153 and LDH levels, had poor pulmonary function test results, or had a UIP-like pattern on chest HRCT were more likely to have indications for the progression of f-ILD to PPF. Increased SPAP and AE are independent risk factors for the prognosis of PPF patients, so additional attention should be given to such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.